Tecentriq + Avastin approved by Health Canada for unresectable or metastatic hepatocellular carcinoma.- Genentech/Roche

Hoffmann-La Roche Limited announced that Health Canada has granted market authorization for Tecentriq (atezolizumab for injection), in combination with Avastin (bevacizumab), for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy.This authorization is based on results from the randomized Phase III IMbrave 150 study. The study showed Tecentriq in combination with bevacizumab reduced the risk of death (overall survival; OS) by 42% (hazard ratio [HR]=0.58; 95% CI: 0.42-0.79; p=0.0006) and reduced the risk of disease worsening or death (progression-free survival; PFS) by 41% (HR=0.59; 95% CI: 0.47-0.76; p<0.0001), compared with sorafenib,[16] the current standard of care for the treatment of hcc in canada. imbrave150 is the first phase iii cancer immunotherapy study to show an improvement in os and pfs in people with unresectable hcc compared with sorafenib. this marks the first time in more than a decade that a new treatment showed a significant improvement and a clinical benefit over standard of care for patients with unresectable hcc.>